Primary Aldosteronism Screening Kit Using Magnetic Bead Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing primary aldosteronism face challenges due to cross-reactivity in aldosterone/renin activity tests, interference from therapeutic drugs, and differential diagnosis complexities, leading to inconsistent results and potential misdiagnosis.
Innovation Solution
A screening kit and diagnosis system using magnetic beads with a balanced hydrophilic-lipophilic polymer to extract and detect aldosterone, angiotensin I, angiotensin II, cortisol, and 18-hydrocorticosterone simultaneously via liquid chromatography-tandem mass spectrometry, with a cut-off ARR value of 20.4 for accurate diagnosis and typing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If immunoassay methods (radioimmunoassay or chemiluminescent immunoassay) are used to measure aldosterone, then the test is rapid and easy to implement, but cross-reactivity occurs between antibodies and non-eliminated aldosterone metabolites causing significantly overestimated test results (median positive bias is 127%)
Solution Approach 1:
The patent extracts and removes aldosterone metabolites from the sample before performing the immunoassay test. By eliminating the interfering metabolites that cause cross-reactivity, the test achieves both ease of implementation and improved accuracy, resolving the contradiction between operational simplicity and measurement precision.
Solution Approach 2:
The patent introduces an intermediary step (metabolite elimination process) between sample collection and testing. This intermediary action removes the harmful cross-reacting substances while preserving the target aldosterone, allowing the immunoassay to proceed accurately without the original precision problems.
2Reliability
If patients withdraw conventional hypotensive drugs for 4-6 weeks during screening to eliminate drug interference, then false-positive or false-negative results are reduced, but this causes certain difficulties to the clinical implementation of screening items
Solution Approach 1:
The patent performs preliminary elimination of aldosterone metabolites from the sample before conducting the screening test. This preliminary action removes the interfering substances that would otherwise require long drug withdrawal periods, allowing accurate screening to be performed without the 4-6 week withdrawal requirement, thus resolving the contradiction between reliability and ease of operation.
3Measurement precision
If multiple test methods are used for confirmed diagnosis (oral administration of diet high-sodium, fludrocortisone test, saline solution test, or captopril test), then diagnosis accuracy is improved, but test complexity and time consumption increase
Solution Approach 1:
The patent combines the metabolite elimination step with the standard screening test procedure into a single integrated workflow. By merging these functions, the system achieves the diagnostic accuracy of multiple tests while maintaining the simplicity of a single test protocol, resolving the contradiction between measurement precision and device complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more accurate and reliable method for early detection and typing of primary aldosteronism, improving sensitivity and specificity, and reducing the impact of drug interference and matrix effects, enabling effective therapeutic interventions.
Implementation Method 1
a magnetic bead with a balanced hydrophilic-lipophilic polymer bonded on the surface
Implementation Method 2
detected by liquid chromatography-tandem mass spectrometry
Implementation Method 3
liquid chromatography-tandem mass spectrometry
Data Source
AI summary
In a screening kit and a confirmed and typing diagnosis system for primary aldosteronism, a sample is pretreated by a magnetic bead bonded with a balanced hydrophilic-lipophilic polymer on the surface thereof, and process conditions are optimized and the content of each the five markers such as, aldosterone in the sample is accurately detected by liquid chromatography-tandem mass spectrometry for one time, thus finding the optimal screening cut-off value of 20.4; when a positive result is judged, PA is confirmed and subjected to typing diagnosis according to the test values of the markers, thereby achieving the simultaneous detection of the content of each the five markers such as, aldosterone on the same platform. Therefore, the screening kit and confirmed and typing diagnosis system for primary aldosteronism are integrated with screening, confirmed and typing diagnosis functions, thus providing a reliable laboratory examination basis for clinicians to formulate an effective therapeutic regimen.